(Q33397605)

English

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

11

object named as

Michael Hallek

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Slawomira Kyrcz-Krzemien

7

object named as

Sławomira Kyrcz-Krzemień

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Thomas Elter

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Liana Gercheva-Kyuchukova

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Halyna Pylylpenko

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tadesuz Robak

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Branimir Jaksic

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Grigoriy Rekhtman

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mykola Vatutin

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jingyang Wu

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cynthia Sirard

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andreas Engert

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

10 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1204-1213

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

How I treat CLL up front

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Update in the management of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

State-of-the-art treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy-related leukemia and myelodysplasia: susceptibility and incidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970242-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70242-X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33397605&oldid=1744295807"